Two winners tied for first place and one received an honorable mention in the Vasculitis Foundation’s (VF) 2020 Recognizing Excellence in Diagnostics (V-RED) award program. Now in its seventh year, the program calls on patients worldwide to nominate a medical professional they want to recognize for making a critical, early…...
VF Announces Young Investigator Award
Dragana Odobasic, PhD, a research fellow at Monash University in Melbourne, Australia, was awarded the Vasculitis Foundation’s (VF) “Dr. Chris Cox-Marinelli Young Investigator Award” in May for her study, Tolerogenic Dendritic Cells for Antigen-Specific Immunosuppression in MPO-ANCA Vasculitis. The award, a one-year grant totaling $49,822, was created in memory of…...
FDA Approves Otezla®for the Treatment of Oral Ulcers in Behcet’s Disease
Celgene Corporation announced on July 19 that the U.S. Food and Drug Administration (FDA) has approved Otezla® (apremilast) 30 mg twice daily (BID) for the treatment of adult patients with oral ulcers associated with Behcet’s disease. Otezla, an oral, selective inhibitor of phosphodiesterase 4 (PDE4), is the first and only…...
Penn’s Giant Cell Arteritis Fast-Track Program Provides Rapid Evaluation
The tricky part of giant cell arteritis (GCA) is the need for rapid evaluation, given the high risk of rapid vision loss and the importance of getting appropriate diagnostic tests, such as a temporal artery biopsy, soon after starting treatment. Unfortunately, there are not a lot of outpatient programs that…...
